wer kann was zu Neurocrine (900964) sagen - 500 Beiträge pro Seite

[azeaze]

Wer kann etwas zu Neurocrine (WKN: 900964) sagen. Dies ist ein sehr interresanter Wert, der noch nicht so weit gegangen ist und in dem noch sehr viel Potenzial steckt.

[make_me_rich]

Viel Spass beim lesen.
Gruß
mmr



Neurocrine Biosciences, Inc. NBIX Nasdaq-NM Click here for
Comparison Charts
Powered by Cognos

Last Sale: $ 32 Net Change: 2.0625
Share Volume: 92,800 Previous Close: $ 29.9375
52 week high: $ 47.5 52 week low: $ 3.75
P/E Ratio: NE Total Shares Outstanding: 19,082,000
Earnings Per Share (EPS):** $ -1.25 Market Cap: $ 610,624,000
Current Yield: N/A Dividend Amount: N/A
Ex Dividend Date: N/A Beta:* 1.17
* S&P 500 used in calculation of Beta
** Latest Four Quarters


Neurocrine Biosciences, Inc. Announces Small Molecule GnRH Antagonist Program Targeting Women`s Health

SAN DIEGO, March 14 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Neurocrine GnRH small molecule antagonist program has accomplished two significant milestones. The company announced that it has developed small molecule GnRH antagonist compounds for the treatment of endometriosis, uterine fibroids, prostate/breast cancer and other related diseases and plans to be in human clinical trials within one year. In addition, the company has been awarded an NIH Phase I grant supporting Neurocrine`s research and development efforts. In contrast to currently marketed GnRH peptide agonists which must be administered via depot injection, such as Lupron(TM) and Zoladex(TM), Neurocrine`s GnRH program is focused on the development of orally active small molecule GnRH antagonists. In addition to the obvious advantages of oral vs. injectable therapy, antagonism of GnRH has been shown it leads to a more rapid suppression of gonadotropins without the flare associated with agonists. Currently marketed GnRH peptides that treat a variety of indications where shutdown or partial inhibition of the reproductive endocrine system is beneficial, generate annual sales in excess of $1.5 billion. These indications include uterine fibroids, endometriosis, prostate cancer, breast cancer and assisted reproductive therapy among others.

GnRH is a ten amino acid peptide whose principal action is to stimulate the secretion of the pituitary gonadotropins. The gonadotropins, in turn, regulate steroid production and gametogenesis in the gonads. Peptide drugs that mimic or inhibit the action of GnRH have proven extremely useful in regulating the hypothalamic-pituitary-gonadal axis and are now routinely used for medical oophorectomy and in a variety of assisted reproductive therapy approaches. Small molecule, orally active GnRH antagonists may provide substantial advantages over existing peptide drugs.

"The GnRH program represents a natural progression of the company`s broad research platform enabling the rapid development of small molecule antagonists against G-protein coupled receptors (GPCR)," said Wylie Vale, Professor, The Salk Institute of La Jolla and co-founder of Neurocrine, a leading researcher in neuropeptides, including CRF and GnRH. "Neurocrine researchers have repeatedly demonstrated their ability to develop GPCR ligands that show promise for the treatment of a number of central nervous, immune and endocrine systems disorders," said Vale. "This particular project builds upon the in-house biological expertise of Dr. Nick Ling, Senior Director Peptide Chemistry, who had worked on the original isolation and characterization of the GnRH peptide in the laboratory of Nobel laureate, Dr. Roger Guillemin." Dr. Ling is a recipient of the 1994 Sydney H. Ingbar Distinguish Service Award in the Field of Endocrinology given by The Endocrine Society and co-authored over 450 papers during his distinguished career.

Neurocrine scientists, led by project leader Dr. Scott Struthers, using the Company`s GPCR focused, high throughput synthesis and biological assay technologies, have rapidly developed multiple families of potent small molecule antagonists with high affinity for the human receptor.

"This is yet another example of the strength of Neurocrine`s core GPCR platform. The GnRH program capitalizes on this platform and the power of the integrated research and development approach underlying Neurocrine`s programs. We feel that receipt of the NIH award provides peer review validation of the program as well as funding through outside sources," said Paul W. Hawran, Senior Vice President and CFO. "We expect to bring a small molecule GnRH antagonist compound into clinical trials in 2001."

Neurocrine Biosciences is a leading neuroscience company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The Company`s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

Neurocrine Biosciences, Inc. news releases are available free of charge through PR Newswire`s Company News On-Call fax service. For a menu of Neurocrine`s previous releases, or to receive a specific release via fax call: [phone], ext. 604138, or use the Internet via http://www.prnewswire.com.

In addition to historical facts, this press release may contain forward- looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward looking statements are risks and uncertainties associated with Neurocrine`s research and development programs and business and finances including, but not limited to, risks and uncertainties associated with, or arising out of, drug discovery, pre-clinical and clinical development of products including risk that research may not generate development candidates, development candidates will not successfully proceed through early clinical trials or that in later stage clinical trials will not show that they are effective in treating humans; determinations by regulatory and governmental authorities; changes in relationships with strategic partners and dependence upon strategic partners for performance of clinical and commercialization activities under collaborative agreements including potential for any collaboration agreement to be terminated without any product success; uncertainties relating to patent protection and intellectual property rights of third parties; impact of competitive products and technological changes; availability of capital and cost of capital; and other material risks. A more complete description of these risks can be found in the Company`s Form 10K for December 31, 1998. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


/CONTACT: Claudia Jones or Paul Hawran of Neurocrine Biosciences, Inc., 858-658-7600/

[nobsi]

Hallo zusammen.
Ich zitiere das Heft "Der Aktionär" vom 09.03.2000.
... Fazit : Aufgrund der enormen Prodiktpalette, die die Abhängigkeit
von einem einzelnen Produkt ausschließt, empfehlen wir die Aktie als
interessante Ergänzung zum Kauf. ...

Ich denke, das es eine relativ "sichere" Biotech-Aktie ist.
(wenn es sowas überhaupt gibt)
Da die Aktie in dieser Woche ganz schön verloren hat, dürfte sie
inzwischen noch interessanter geworden sein.
Ich habe jedenfalls einige geordert ... ;-)
Aber das bleibt ja jedem selbst überlassen.

(übrigens, ich bin neu. ich werde jetzt öfters mal vorbeischauen)

[azeaze]

dank an make_me_rich und nobsi.

übrigens, neurocrine heute am nasdaq +16,5%

[SharkofDark]

Hi ihr Bio-Freaks,

bin ebenfalls seit kurzem in die Aktie investiert. Der Kursanstieg seit Dez.99 ist mit dem allgemeinen Biotech. Boom zu erklären. Die wirkliche Kursexplosion durch neue Produkte, welche jetzt noch in der Pipeline sind, wird noch bevor stehen. Das kann morgen oder erst in einem Jahr sein...egal, scheinbar gutes Ivestment, bleibt dabei Leute

[The_Edge]

Klarer Kauf, so günstig wie lange nicht mehr, Tip für heute +12%

[Gaderl]

Was war gestern an der Nasdaq mit Neurocrine los???
Wer weis was?